Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuritis - Overview
Optic Neuritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuritis - Companies Involved in Therapeutics Development
Bionure Farma SL
Commence Bio Inc
EnhanX Biopharm Inc
Japan Innovative Therapeutics Inc
Meta-IQ ApS
Mitochon Pharmaceuticals Inc
Noveome Biotherapeutics Inc
SanBio Inc
Optic Neuritis - Drug Profiles
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etomoxir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gypenoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Optic Neuritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Optic Neuritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuritis - Dormant Projects
Optic Neuritis - Discontinued Products
Optic Neuritis - Product Development Milestones
Featured News & Press Releases
May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer
May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retil ganglion cells
May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201
Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO
May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Optic Neuritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Optic Neuritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuritis - Pipeline by Bionure Farma SL, H1 2020
Optic Neuritis - Pipeline by Commence Bio Inc, H1 2020
Optic Neuritis - Pipeline by EnhanX Biopharm Inc, H1 2020
Optic Neuritis - Pipeline by Japan Innovative Therapeutics Inc, H1 2020
Optic Neuritis - Pipeline by Meta-IQ ApS, H1 2020
Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2020
Optic Neuritis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Optic Neuritis - Pipeline by SanBio Inc, H1 2020
Optic Neuritis - Dormant Projects, H1 2020
Optic Neuritis - Discontinued Products, H1 2020